Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Hemasphere|February 8, 2023
Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma PatientsAikaterini Panopoulou, Sandra Easdale, Mark Ethell, et al.
Blood|May 24, 2013
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myelomaMartin F Kaiser, David C Johnson, Ping Wu, et al.
Blood|January 16, 2026
Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20Alex Y Ge, William B Feldman, Martin F Kaiser, et al.
Leukemia & Lymphoma|December 29, 2012
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myelomaAnnamaria Brioli, Martin F Kaiser, Charlotte Pawlyn, et al.
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
Blood Advances|July 8, 2026
AI derived Whole-Body MRI metrics in multiple myeloma patients reveal unique insights into body composition and outcomesNicolas Basty, Martin F Kaiser, Charlotte Pawlyn, et al.
Plos One|June 14, 2014
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complexFabio Mirabella, Alexander Murison, Lauren I Aronson, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Pageof 6